Type 1 Diabetes

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A study found that dried blood spot screening can identify presymptomatic type 1 diabetes in children, reducing the risk of diabetic ketoacidosis.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Clinicians reviewed evidence linking delayed diagnosis of type 1 diabetes to lasting neurologic and metabolic consequences.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

See the full case of our most recent puzzler quiz, and view the correct diagnosis of this slender teen with a growing abdomen and shrinking height.

A review highlights the benefits and risks of artificial sweeteners in glycemic control, insulin sensitivity, and gut microbiota balance.

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence.

FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes.

The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.

Michael Haller, MD, tell providers they shouldn't be surprised if more children with T1D use inhaled insulin.

Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.

Manufacturer MannKind has submitted a supplemental Biologics Application to the FDA for its inhaled insulin Afrezza.

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

A 40-year study found that higher third-trimester glucose levels in insulin-dependent pregnancies were tied to increased obesity risk in adult offspring.

The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

Greg Forlenza, MD, highlights data from the CLVer trial that included advanced diabetes technology in newly diagnosed T1D patients.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.

A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.